234 related articles for article (PubMed ID: 24516103)
1. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
Hypertension; 2014 May; 63(5):951-7. PubMed ID: 24516103
[TBL] [Abstract][Full Text] [Related]
2. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
Marney A; Kunchakarra S; Byrne L; Brown NJ
Hypertension; 2010 Oct; 56(4):728-33. PubMed ID: 20679179
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
[TBL] [Abstract][Full Text] [Related]
4. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition.
Hubers SA; Wilson JR; Yu C; Nian H; Grouzmann E; Eugster P; Shibao CA; Billings FT; Jafarian Kerman S; Brown NJ
Hypertension; 2018 Sep; 72(3):712-719. PubMed ID: 29987109
[TBL] [Abstract][Full Text] [Related]
5. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.
Van Guilder GP; Pretorius M; Luther JM; Byrd JB; Hill K; Gainer JV; Brown NJ
Hypertension; 2008 Feb; 51(2):454-9. PubMed ID: 18180402
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women.
Wilson JR; Brown NJ; Nian H; Yu C; Bidlingmaier M; Devin JK
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478970
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ
Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.
Byrd JB; Touzin K; Sile S; Gainer JV; Yu C; Nadeau J; Adam A; Brown NJ
Hypertension; 2008 Jan; 51(1):141-7. PubMed ID: 18025295
[TBL] [Abstract][Full Text] [Related]
10. DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.
Wilson JR; Garner EM; Mashayekhi M; Hubers SA; Ramirez Bustamante CE; Kerman SJ; Nian H; Shibao CA; Brown NJ
Hypertension; 2022 Apr; 79(4):827-835. PubMed ID: 35045722
[TBL] [Abstract][Full Text] [Related]
11. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.
Benjamin N; Cockcroft JR; Collier JG; Dollery CT; Ritter JM; Webb DJ
J Physiol; 1989 May; 412():543-55. PubMed ID: 2557432
[TBL] [Abstract][Full Text] [Related]
12. Quinaprilat-induced vasodilatation in forearm vasculature of patients with essential hypertension: comparison with enalaprilat.
Houben AJ; Kroon AA; de Haan CH; Fuss-Lejeune MJ; de Leeuw PW
Cardiovasc Drugs Ther; 2000 Dec; 14(6):657-63. PubMed ID: 11300367
[TBL] [Abstract][Full Text] [Related]
13. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
Jackson EK; Mi Z; Tofovic SP; Gillespie DG
Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
[TBL] [Abstract][Full Text] [Related]
14. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin.
Prasad A; Husain S; Quyyumi AA
J Am Coll Cardiol; 1999 Mar; 33(3):796-804. PubMed ID: 10080484
[TBL] [Abstract][Full Text] [Related]
15. 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women.
Pretorius M; van Guilder GP; Guzman RJ; Luther JM; Brown NJ
Hypertension; 2008 Apr; 51(4):1190-6. PubMed ID: 18259028
[TBL] [Abstract][Full Text] [Related]
16. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.
Wilson JR; Kerman SJ; Hubers SA; Yu C; Nian H; Grouzmann E; Eugster PJ; Mayfield DS; Brown NJ
J Endocr Soc; 2019 Oct; 3(10):1784-1798. PubMed ID: 31528826
[TBL] [Abstract][Full Text] [Related]
18. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
Petrie MC; Padmanabhan N; McDonald JE; Hillier C; Connell JM; McMurray JJ
J Am Coll Cardiol; 2001 Mar; 37(4):1056-61. PubMed ID: 11263608
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
Abouelkheir M; El-Metwally TH
Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
